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Markov type model to model disease progression. For each intervention (including no drug intervention), in each period, every woman faced some risk of an event. For example, fracture (vertebral or hip), myocardial infarction (MI; fatal or nonfatal), or breast cancer (differentiated by stage at diagnosis). The health events excluded were other osteoporotic fractures, non-MI coronary heart disease, uterine cancer and venous thromboembolic events. The model had a 7-year time horizon. The Markov cycle length appears to have been 1 year.
Outcomes assessed in the review
The clinical outcomes included vertebral and hip fractures, fatal and nonfatal MI, and breast cancer. Rates of persistence (i.e. the percentage of women who have not discontinued therapy) with the different therapies were also considered.
Study designs and other criteria for inclusion in the review
Not all of the study designs were reported. Most of the studies used to populate the model parameters of effectiveness appear to have been randomised controlled trials or pooled placebo-controlled trials, as well as some observational studies. Rates of persistence with therapy were taken from an observational study from a large managed care organisation and another study, the design of which was not reported.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Nineteen studies were included to inform the effectiveness inputs for the model.
Methods of combining primary studies
A narrative method was used to combine the primary studies.
Investigation of differences between primary studies
Results of the review
The relative risk decreases or increases of the different strategies compared with no prescription drug for the different years (Y) were as follows.
With CEE+MPA:
hip fractures, -18% (Y1) and -35% (>Y1); vertebral fractures, -45% (Y1) and -35% (>Y1); breast cancer, 0% (Y1-Y4) and +25% (>Y4); coronary heart disease (CHD), +75% (Y1), +15% (Y2) and 0% (>Y2).
With raloxifene: hip fractures, 0%;
vertebral fractures, -65% (Y1) and -50% (>Y1); breast cancer, 0% (Y1) and -55% (>Y1); CHD, 0% (Y1-Y2) and -15% (>Y2).
With alendronate:
hip fractures, -25% (Y1) and -50% (>Y1); vertebral fractures, -60% (Y1) and -50% (>Y1); breast cancer and CHD, 0%.
The authors reported that all assumptions about risk reductions in efficacy and safety were rounded to the nearest 5%.
The persistence rates were assumed to be equal for all three drugs in the base-case model. It was assumed that 41% of the patients were persistent at the end of the first year and 26% (Y2), 19% (Y3), 17% (Y4), 15% (Y5), 14% (Y6) and 13% (Y7) at the end of subsequent years.
Methods used to derive estimates of effectiveness
The authors made assumptions, based mostly on the literature, to derive estimates.
Estimates of effectiveness and key assumptions
To be conservative, the base-case model scenario assumed no fracture prevention efficacy for raloxifene at the hip, and a 2-year lag for a reduction in the risk of CHD. The base-case model scenario assumed that the persistence rates across all three therapy arms were identical to the rate assumed for CEE+MPA. Other assumptions were that side effects occurred during the first year and ended with drug discontinuation.
Measure of benefits used in the economic analysis
The measure of benefits used was the number of clinical events prevented (vertebral and hip fractures, CHD and breast cancer).
Direct costs
The quantity/cost boundary adopted was that of the health service. The health service costs were the annual drug costs (assumed to require one physician visit), the costs of side effects of therapy, and direct medical savings or costs of related events (hip and vertebral fracture, fatal and nonfatal MI, breast cancer treatment according to stage at diagnosis). The resource use data were derived from the literature, while the costs were obtained from different sources. More specifically, the average wholesale price for drugs, Medicare payment rates for resource use for side effects, and different studies for the direct costs of other events. The total costs were derived using modelling. Discounting was not undertaken, which was inappropriate due to the medium-term time horizon of the study. The unit costs and the resource quantities were not reported separately. The price year was 2000. The costs from the literature were converted to 2000-equivalent dollars using the medical care component of the consumer price index.
